Key terms
About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATRC news
Feb 16
8:52am ET
AtriCure price target lowered to $42 from $50 at Stifel
Feb 16
8:07am ET
Stifel Nicolaus Remains a Buy on Atricure (ATRC)
Feb 16
7:57am ET
Oppenheimer Sticks to Its Hold Rating for Atricure (ATRC)
Feb 16
7:34am ET
Atricure’s Strong Growth and Positive 2024 Outlook Merit a Buy Rating
Feb 16
7:28am ET
AtriCure price target raised to $57 from $52 at Canaccord
Feb 16
7:27am ET
Atricure’s Strong Growth and Market Position Justify Buy Rating and $65 Target Price
Feb 16
7:20am ET
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Charles River Labs (CRL) and Shockwave Medical (SWAV)
Feb 16
7:18am ET
AtriCure price target raised to $58 from $57 at UBS
Feb 16
5:55am ET
Atricure’s Strong Performance and Growth Potential Merit a Buy Rating
Feb 16
2:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 15
4:04pm ET
AtriCure sees FY24 EPS (82c) to (74c), consensus (69c)
Feb 15
4:03pm ET
AtriCure reports Q4 EPS (21c), consensus (23c)
Jan 22
7:01am ET
AtriCure price target raised to $52 from $50 at Canaccord
Jan 09
7:47am ET
AtriCure’s Growth Trajectory: A Strong Buy Rating with Revenue Surge and Strategic Expansions
Jan 08
1:25pm ET
Atricure’s Strong Growth and Positive Outlook Justify Buy Rating
Jan 08
10:10am ET
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Ascendis Pharma (ASND) and G1 Therapeutics (GTHX)
Jan 08
8:11am ET
AtriCure sees FY24 revenue $459M-$466M , consensus $454.68M
Jan 08
8:09am ET
AtriCure sees FY23 EPS (76c)-(74c), consensus (74c)
Jan 07
5:50am ET
Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT), Apollo Medical Holdings (AMEH) and Atricure (ATRC)
Jan 04
8:08am ET
AtriCure price target lowered to $44 from $49 at Needham
Jan 04
6:40am ET
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and AbbVie (ABBV)
Jan 02
9:07am ET
Atricure (ATRC) Gets a Buy from BTIG
Dec 31
5:06am ET
BTIG Keeps Their Buy Rating on Atricure (ATRC)
Dec 21
8:40am ET
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Akoya Biosciences (AKYA)
Nov 29
12:30am ET
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Ambrx Biopharma (AMAM)
Nov 28
2:25pm ET
Atricure’s Strong Market Position Justifies Buy Rating Despite New Competition
No recent news articles are available for ATRC
No recent press releases are available for ATRC
ATRC Financials
Key terms
Ad Feedback
ATRC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATRC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range